News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News July 8, 2026
Advised TGS on Sale of Its North American Well Data Products Business to Enverus
Gibson Dunn advised TGS, a leading provider of energy data and intelligence, on the sale of its North American well data products business to Enverus, Inc.
Firm News April 27, 2026
Gibson Dunn Expands European Transactional Platform With New Madrid Office
Gibson Dunn announced today the opening of its Madrid office, marking a significant milestone in the firm's continued European expansion and reinforcing its commitment to serving clients in one of the continent's most dynamic transactional markets.
Article March 26, 2026
Angelique Kaounis and Joseph Gorman Reflect on “High Tech Stakes” for Los Angeles Lawyer
Partner Angelique Kaounis and of counsel Joseph Gorman have published “High-Tech Stakes (2010), Revisited” in Los Angeles Lawyer — a commentary on Kaounis’s original 2010 article addressing the challenges of handling confidential information in potential technology-focused acquisitions.
Firm News February 5, 2026
Gibson Dunn Advises Igneo on Acquisition of Vault Digital, a 75 MW U.S. Wholesale Data Center Portfolio
Gibson Dunn advised Igneo Infrastructure Partners, a global infrastructure investment manager with $23 billion in assets under management, on its acquisition of an approximately 75 MW, 750,000 sf portfolio of seven operational data centers across key U.S. markets from CVC DIF and Northleaf Capital Partners.
Firm News January 23, 2026
Gibson Dunn Advises BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics
Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility, to finance, in part, the acquisition of Astria Therapeutics, Inc.
Firm News November 5, 2025
Gibson Dunn Advises Ultragenyx on $400 Million Sale of a Portion of Future North American Royalties on Crysvita® (burosumab)
Gibson Dunn is advising Ultragenyx Pharmaceutical Inc. on its sale of a portion of future North American royalties on Crysvita® …
Firm News August 13, 2025
Gibson Dunn Advises XOMA Royalty Corporation on Acquisition of HilleVax, Inc.
Gibson Dunn is representing XOMA Royalty Corporation, a publicly traded biotech royalty aggregator, on its acquisition of HilleVax, Inc. (Nasdaq: …
Firm News July 28, 2025
Gibson Dunn Advises US WorldMeds on Acquisition of Adaptimmune Therapeutics’s TECELRA, lete-cel, afami-cel, and uza-cel Cell Therapies and Concurrent Financing
Gibson Dunn is advising US WorldMeds, a specialty pharmaceutical company, on its acquisition of Adaptimmune Therapeutics’s TECELRA, lete-cel, afami-cel, and …